Delaying the LymPro data is a strategic move. As w
Post# of 30028
Posted On: 12/29/2014 7:53:31 AM
Delaying the LymPro data is a strategic move. As we've seen from the Retinitis Orphan announcement, it didn't move the stock price at all. Even if Gerald had released the Lympro data today and it had been good, it probably wouldn't have done anything to the stock price. I suspect delaying it 2 weeks allows them to close a sale or two from pharmas wanting to use LymPro and Gerald thinks he'll get a much bigger bang out of the announcement if he releases the data along with the announcement of sales.
I don't blame Gerald for doing this. The market is interested in revenue. Commitments from pharmas that they'll use Lympro is the next best thing. You can't blame Gerald for timing the release of the data to get the biggest possible bang.
I don't blame Gerald for doing this. The market is interested in revenue. Commitments from pharmas that they'll use Lympro is the next best thing. You can't blame Gerald for timing the release of the data to get the biggest possible bang.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼